These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 10529861)

  • 1. [The pharmacological inhibition of the intracellular signals involved in cellular proliferation: a cardiovascular approach].
    Villanueva LA; Guarner V
    Arch Inst Cardiol Mex; 1999; 69(3):265-71. PubMed ID: 10529861
    [No Abstract]   [Full Text] [Related]  

  • 2. [How the therapy of cancer is changing].
    Lopez M
    Clin Ter; 1999; 150(6):397-400. PubMed ID: 10756657
    [No Abstract]   [Full Text] [Related]  

  • 3. [Signal transduction inhibitor].
    Ueda Y; Saijo N
    Gan To Kagaku Ryoho; 2001 May; 28(5):591-600. PubMed ID: 11383206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of N-myc in neuroblastoma by autocrine IGF-II depends on farnesylated Ras. Application of farnesyltransferase inhibitors.
    Wittrock J; Schweizer P; Girgert R
    Anticancer Res; 2002; 22(6C):4205-9. PubMed ID: 12553057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parallel signaling pathways in endothelin-1-induced proliferation of U373MG astrocytoma cells.
    He S; Dibas A; Yorio T; Prasanna G
    Exp Biol Med (Maywood); 2007 Mar; 232(3):370-84. PubMed ID: 17327470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
    Feldkamp MM; Lau N; Guha A
    Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.
    Graaf MR; Richel DJ; van Noorden CJ; Guchelaar HJ
    Cancer Treat Rev; 2004 Nov; 30(7):609-41. PubMed ID: 15531395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rac1 and Rac3 are targets for geranylgeranyltransferase I inhibitor-mediated inhibition of signaling, transformation, and membrane ruffling.
    Joyce PL; Cox AD
    Cancer Res; 2003 Nov; 63(22):7959-67. PubMed ID: 14633727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents.
    Ohkanda J; Blaskovich MA; Sebti SM; Hamilton AD
    Prog Cell Cycle Res; 2003; 5():211-7. PubMed ID: 14593715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta.
    Adnane J; Bizouarn FA; Chen Z; Ohkanda J; Hamilton AD; Munoz-Antonia T; Sebti SM
    Oncogene; 2000 Nov; 19(48):5525-33. PubMed ID: 11114730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ras farnesyltransferase inhibition: a novel and safe approach for cancer chemotherapy.
    Nammi S; Lodagala DS
    Acta Pharmacol Sin; 2000 May; 21(5):396-404. PubMed ID: 11324435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic cell fate and the initiation of leukemic properties in primitive primary human cells are influenced by Ras activity and farnesyltransferase inhibition.
    Dorrell C; Takenaka K; Minden MD; Hawley RG; Dick JE
    Mol Cell Biol; 2004 Aug; 24(16):6993-7002. PubMed ID: 15282300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
    Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A farnesyltransferase inhibitor attenuates cardiac myocyte hypertrophy and gene expression.
    Calderone A; Abdelaziz N; Colombo F; Schreiber KL; Rindt H
    J Mol Cell Cardiol; 2000 Jun; 32(6):1127-40. PubMed ID: 10888263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effects of ethanol on rat mesangial cell proliferation via protein kinase C pathway.
    Segawa K; Minami K; Uezono Y; Shiraishi M; Shigematsu A
    Alcohol Clin Exp Res; 2002 Mar; 26(3):358-62. PubMed ID: 11923589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
    Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
    Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesyltransferase inhibitors.
    Adjei AA
    Cancer Chemother Biol Response Modif; 2002; 20():151-67. PubMed ID: 12703204
    [No Abstract]   [Full Text] [Related]  

  • 18. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
    Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of signaling in myelodysplastic syndrome.
    Gore SD
    Best Pract Res Clin Haematol; 2004 Dec; 17(4):613-22. PubMed ID: 15494298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ras processing as a therapeutic target in hematologic malignancies.
    Le DT; Shannon KM
    Curr Opin Hematol; 2002 Jul; 9(4):308-15. PubMed ID: 12042705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.